Form 4: Whitehawk Therapeutics CFO Giacobello Receives Stock Options and Restricted Stock Units

Scott M. Giacobello, CFO of Whitehawk Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) as part of his compensation.

Summary

• Scott M. Giacobello, the Chief Financial Officer of Whitehawk Therapeutics, Inc., filed a Form 4 on April 3, 2025, reporting changes in his beneficial ownership of the company's securities.
• The reported transactions include the acquisition of stock options to purchase 473,902 shares of common stock at an exercise price of $1.70 per share.
• Giacobello also acquired 473,902 restricted stock units (RSUs), each representing a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
• Both the stock options and RSUs vest subject to Giacobello's continued service with the company, as defined in the Issuer's 2021 Equity Incentive Plan.
• The stock options vest 25% on the one-year anniversary of the Vesting Commencement Date (April 1, 2025), and then 1/48th monthly thereafter, fully vesting on the four-year anniversary.
• The RSUs vest 100% on the one-year anniversary of the Vesting Commencement Date (April 1, 2025).

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity suggests confidence in the company's future, but it's a routine transaction.

Positives

• The granting of stock options and RSUs to the CFO aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• The vesting schedules encourage continued service and commitment from the CFO.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Whitehawk Therapeutics' stock, which is subject to market risks and company-specific factors.
• If the CFO leaves the company before the options and RSUs fully vest, he will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of future value creation.

Industry Context

Granting stock options and RSUs to key executives is a common practice in the biotechnology industry to attract and retain talent and align their interests with those of shareholders. This is especially true for smaller companies where cash compensation may be limited.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron routinely grant stock options and RSUs to their executives.
• The vesting schedules (one year for RSUs, four years for options) are typical for such grants.

Stakeholder Impact

• Shareholders may view the equity grants positively as aligning management's interests with theirs.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, RSUs, Form 4, beneficial ownership, Whitehawk Therapeutics, Giacobello, CFO, vesting